Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cell therapy (Dr. Grant M. Pagdin)
- Development stage
- Unknown
- Lead developer
- Dr. Grant M. Pagdin
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
This autologous cell therapy is a combination treatment modality developed and investigated by Dr. Grant M. Pagdin for the treatment of osteoarthritis in major joints, including the knee, hip, and shoulder. The therapy involves the harvesting and concentrated re-injection of a patient's own biological materials: platelet-rich plasma (PRP), lipoaspirate (containing adipose-derived mesenchymal stem cells), and bone marrow aspirate concentrate (containing bone marrow-derived mesenchymal stem cells). Classified as an autologous cell therapy product (ACTP) by Health Canada, the treatment aims to deliver a high concentration of mesenchymal stem cells and growth factors directly to the affected joint. These components are intended to modulate the local inflammatory environment, reduce pain, improve joint function, and potentially facilitate tissue regeneration. The therapy is currently being evaluated in a Phase II randomized clinical trial (NCT03984461) conducted by Pagdin Health in Kelowna, British Columbia.
- Brand names
- AdiPrepMarrow CellutionsHarvest PRP
- Other names
- Autologous cell therapyAutologous cell therapy productACTPPRP plus lipoaspiratePRP plus bone marrow aspiratePRP plus lipoaspirate and bone marrow aspirate
Beyond the preview
Go deeper on autologous cell therapy (Dr. Grant M. Pagdin).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cell therapy (Dr. Grant M. Pagdin).